Results 1 to 10 of about 33,137 (128)

Treating and Preventing Influenza in Aged Care Facilities: A Cluster Randomised Controlled Trial [PDF]

, 2012
PMCID: PMC3474842This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are ...
Alexander E. Rosewell, Anna S. Dean, C. Raina MacIntyre, Cameron R. M. Moffatt, Clayton K. Chiu, D. William Cameron, David J. Philp, Dominic E. Dwyer, Jiehui K. Yin, Leon G. Heron, Richard I. Lindley, Robert Booy, Timothy Dobbins, Zhanhai Gao   +13 more
core   +25 more sources

Oseltamivir for influenza [PDF]

The Lancet, 2015
Table: Number of admittances to hospital in trials whose analysis population was common to both reviews (intention-to-treat population) Meta-analyses of individual patient data hold the potential of off ering new insights into old data, but the Article by Joanna Dobson and colleagues fails to do this, presenting no new data on the potential treatment ...
Jones, Mark, Hama, Rokuro, Del Mar, Chris   +2 more
  +14 more sources

A Practical Synthesis of (−)‐Oseltamivir [PDF]

Angewandte Chemie, 2007
AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Nobuhiro, Satoh, Takahiro, Akiba, Satoshi, Yokoshima, Tohru, Fukuyama   +3 more
openaire   +2 more sources

Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children [PDF]

, 2014
BACKGROUND: Neuraminidase inhibitors (NIs) are stockpiled and recommended by public health agencies for treating and preventing seasonal and pandemic influenza. They are used clinically worldwide.
Del Mar, Chris B., Doshi, Peter, Hama, Rokuro, Heneghan, Carl J., Howick, Jeremy, Jefferson, Tom, Jones, Mark A., Mahtani, Kamal R., Nunan, David, Onakpoya, Igho, Spencer, Elizabeth A., Thompson, Matthew J.   +11 more
core   +1 more source

Psychiatric adverse events in oseltamivir prophylaxis trials: Novel comparative analysis using data obtained from clinical study reports [PDF]

, 2018
PURPOSE: Estimating the rate of adverse events (AEs) caused by a treatment in clinical trials typically involves comparing the proportions of patients experiencing AEs in intervention and control groups.
Bender, Doshi, Gravenstein, Hayden, Jefferson, Jefferson, Jones, Lineberry, Patel, Peters, Simmonds, Toovey, Welliver   +12 more
core   +1 more source

Oseltamivir

Journal of Postgraduate Medicine, 2009
Oseltamivir, a selective neuraminidase enzyme inhibitor, has gained worldwide attention in view of Influenza A (H1N1) pandemic. It is one of the most important drugs effective against the novel influenza virus. Oseltamivir is used for the treatment of uncomplicated acute illness due to influenza infection.
  +5 more sources

Distribution of selected healthcare resources for influenza pandemic response in Cambodia. [PDF]

, 2013
INTRODUCTION: Human influenza infection poses a serious public health threat in Cambodia, a country at risk for the emergence and spread of novel influenza viruses with pandemic potential.
Borin, Khieu, CamFlu Project Collaborators, Chavez, Irwin, Coker, Richard, Drake, Tom, Rudge, James W, Schwanke Khilji, Sara U, Touch, Sok   +7 more
core   +3 more sources

Contact transmission of influenza virus between ferrets imposes a looser bottleneck than respiratory droplet transmission allowing propagation of antiviral resistance [PDF]

, 2016
Influenza viruses cause annual seasonal epidemics and occasional pandemics. It is important to elucidate the stringency of bottlenecks during transmission to shed light on mechanisms that underlie the evolution and propagation of antigenic drift, host ...
Ashcroft, J, Barclay, W, Bradley, K, Donnelly, C, Elderfield, R, Fernandez-Alonso, M, Frise, R, Galiano, M, Lackenby, A, Miah, S, Roberts, K, Stilwell, P, Van Doremalen, N   +12 more
core   +1 more source

Medication Complications in Extracorporeal Membrane Oxygenation. [PDF]

, 2017
The need for extracorporeal membrane oxygenation (ECMO) therapy is a marker of disease severity for which multiple medications are required. The therapy causes physiologic changes that impact drug pharmacokinetics.
Aebi, Ami G. Shah, Anderson, Arlt, Barr, Barthelemy, Beiderlinden, Bein, Bembea, Bhatt-Meht, Boucher, Brandi N. Thoma, Brown, Buck, Buscher, Chung, Dagan, Dagan, de Montmollin, De Rosa, DeGrado, Donadello, Donadello, Dzierba, Erstad, Esper, Eyler, Flordelis Lasierra, Glauber, Greenberg, Gélisse, Hadidi, Hertzog, Hraiech, Hynynen, Johnston, Kawada, Kim, Koster, Krueger, Lamarche, Latronico, Lemaitre, Levison, Malfertheiner, Mehta, Michelle Peahota, Moore, Mousavi, Mulla, Mulla, Muntean, Oliver, Paden, Park, Perkins, Peters, Pettignano, Phillips, Pieri, Potter, Preston, Protti, Ranucci, Riker, Roberts, Roos, Rosen, Ruiz, Rybak, Saini, Sanfilippo, Satyapriya, Schmith, Shekar, Shekar, Shekar, Shekar, Shekar, Sherwin, Sklar, Smith, Spriet, Staudacher, Strunk, Subramaniam, Szefner, Tellor, Trudzinski, Tulman, Turner, Veinstein, Vilay, Wagner, Walter K. Kraft, Welsch, Wen, Wildschut, Wu, Young   +99 more
core   +2 more sources

Adjuvant-containing control arms in pivotal quadrivalent human papillomavirus vaccine trials: Restoration of previously unpublished methodology [PDF]

, 2020
Purpose: Trustworthy reporting of quadrivalent human papillomavirus (HPV) vaccine trials is the foundation for assessing the vaccine's risks and benefits.
Bourgeois, Florence, Doshi, Peter, Hong, Kyungwan, Jefferson, Tom, Jones, Mark, Lee, Haeyoung, Shamseer, Larissa, Spence, O'Mareen   +7 more
core   +1 more source